多囊性肾病产前诊断:诊断率、新致病性变异及基因型-表型关联
本研究纳入2014年1月至2022年6月220例胎儿多囊性肾病病例,分为孤立性多囊性发育不良肾、非孤立性多囊性发育不良肾和疑似多囊性肾病三组。染色体微阵列分析检出19例(8.6%)染色体异常,94个家系行三人组外显子组测序,21例(22.3%)检出致病/可能致病性变异。三组活产率差异有统计学意义(91/130 vs 46/80 vs 1/10;P<.001)。
要点
- 染色体微阵列分析检出19例(8.6%)染色体异常,最常见为17q12微缺失(7/220;3.2%)。
- 94个家系行三人组外显子组测序,21例(22.3%)检出致病/可能致病性变异。
- 138例活产中106例(78.5%)行产后超声复查,其中95例(89.6%)产前与产后超声诊断一致。
核心结论
- 对于孤立性和非孤立性多囊性肾病,染色体微阵列分析和外显子组测序均显示较高检出效率。
- 新致病性变异的检出扩展了多囊性肾病相关基因的已知疾病谱,并丰富了对基因型-表型关联的理解。
- 作者认为在胎儿多囊性肾病中行染色体微阵列分析+外显子组测序是可行的。
- 排除已知遗传病时,产前与产后超声一致性更高、活产率更高、预后更好,提示基因检测结果显著影响妊娠决策。
研究设计与样本
- 本研究纳入2014年1月至2022年6月共220例胎儿多囊性肾病病例。
- 病例分为孤立性多囊性发育不良肾、非孤立性多囊性发育不良肾和疑似多囊性肾病三组。
- 回顾性分析母亲人口学资料、超声结果、染色体微阵列分析/外显子组测序结果及妊娠结局。
主要发现
- 染色体微阵列分析检出19例(8.6%)胎儿携带染色体异常,最常见拷贝数变异为17q12微缺失(7/220;3.2%)。
- 94个家系行三人组外显子组测序,21例(22.3%)检出致病/可能致病性变异。
- 三组活产率分别为91/130、46/80、1/10,差异有统计学意义(P<.001)。
- 138例活产中106例(78.5%)行产后超声复查,其中95例(89.6%)产前与产后超声诊断一致。
临床怎么用
- 作者认为在胎儿多囊性肾病中行染色体微阵列分析+外显子组测序是可行的。
- 基因检测结果显著影响妊娠决策,排除已知遗传病时产前与产后超声一致性更高、活产率更高、预后更好。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Polycystic renal disease is a frequent congenital anomaly of the kidneys, but research using chromosomal microarray analysis and exome sequencing in fetuses with polycystic renal disease remains sparse, with most studies focusing on the multisystem or genitourinary system. OBJECTIVE: This study aimed to assess the detection rate of detectable genetic causes of fetal polycystic renal disease at different levels, novel disease-causing variants, and genotype-phenotype correlations. STUDY DESIGN: This study included 220 fetal polycystic renal disease cases from January 2014 to June 2022. Cases were divided into the following 3 groups: isolated multicystic dysplastic kidneys, nonisolated multicystic dysplastic kidneys, and suspected polycystic kidney disease group. We reviewed data on maternal demographics, ultrasonographic results, chromosomal microarray analysis/exome sequencing results, and pregnancy outcomes. RESULTS: In our cohort, chromosomal microarray analysis identified 19 (8.6%) fetuses carrying chromosomal abnormalities, and the most common copy number variation was 17q12 microdeletion (7/220; 3.2%). Furthermore, 94 families chose to perform trio-exome sequencing testing, and 21 fetuses (22.3%) were found to harbor pathogenic/likely pathogenic variants. There was a significant difference in the live birth rate among the 3 groups (91/130 vs 46/80 vs 1/10; P<.001). Among 138 live birth cases, 106 (78.5%) underwent postnatal ultrasound review, of which 95 (89.6%) had a consistent prenatal-postnatal ultrasound diagnosis. CONCLUSION: For both isolated and nonisolated polycystic renal disease, our data showed high detection efficiency with both testing tools. The detection of novel pathogenic variants expands the known disease spectrum of polycystic renal disease-associated genes while enriching our understanding of the genotype-phenotype correlation. Therefore, we consider it feasible to perform chromosomal microarray analysis+exome sequencing testing in fetal polycystic renal disease. Moreover, prenatal-postnatal ultrasound concordance was greater, the live birth rate was higher, and prognosis was better when known genetic disorders were excluded, indicating that genetic testing results significantly influenced pregnancy decisions.
引用
- Huang R, Fu F, Guo F, et al. Prenatal diagnosis of polycystic renal diseases: diagnostic yield, novel disease-causing variants, and genotype-phenotype correlations. Am J Obstet Gynecol MFM. 2023. PMID: 37984685. doi:10.1016/j.ajogmf.2023.101228
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。